Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Current Liabilities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Total Current Liabilities for 4 consecutive years, with $12.1 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Total Current Liabilities rose 61.57% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Sep 2023, up 61.57%, and an annual FY2022 reading of $8.5 million, up 24.16% over the prior year.
  • Total Current Liabilities was $12.1 million for Q3 2023 at Terns Pharmaceuticals, down from $14.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $22.8 million in Q4 2020 and bottomed at $5.8 million in Q2 2021.
  • Average Total Current Liabilities over 4 years is $9.8 million, with a median of $7.9 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities crashed 70.12% in 2021, then surged 135.57% in 2023.
  • Year by year, Total Current Liabilities stood at $22.8 million in 2020, then tumbled by 70.12% to $6.8 million in 2021, then increased by 24.16% to $8.5 million in 2022, then skyrocketed by 42.74% to $12.1 million in 2023.
  • Business Quant data shows Total Current Liabilities for TERN at $12.1 million in Q3 2023, $14.2 million in Q2 2023, and $12.1 million in Q1 2023.